QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

About this update from Qiagen N.v.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":242,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/1f65749b6be9a33a432d5806ac643906"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mbD99dOI8OgHu3w6IZRNtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1f65749b6be9a33a432d5806ac643906","width":242,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment","length":153,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":153,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER)","length":101,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":101,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target","length":89,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":89,"olType":false},{"type":"text","content":"VENLO, Netherlands, April 06, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers.","length":295,"tagName":"p"},{"type":"text","content":"Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued products such as NeuMoDx and Dialunox). Adjusted diluted EPS are expected to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 CER.","length":387,"tagName":"p"},{"type":"text","content":"Sales of the QuantiFERON latent TB test grew about 15% CER as global adoption continues to shift from the skin test to this proven, modern blood-based test. The QIAstat-Dx syndromic testing system advanced above 35% CER on co...

More updates from Qiagen N.v.